SCM
ALNY icon

Silverarc Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Silverarc Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-35,774
Closed -$9.84M – 64
2024
Q3 		$9.84M Sell
35,774
-226
-0.6% -$58.8K 2.22% 16
2024
Q2 		$8.75M Buy
+36,000
New +$5.68M 2.16% 14
2023
Q2 		– Sell
-14,043
Closed -$2.81M – 84
2023
Q1 		$2.81M Sell
14,043
-23,609
-63% -$4.96M 1.26% 32
2022
Q4 		$8.95M Buy
37,652
+5,107
+16% +$1.09M 3.08% 12
2022
Q3 		$6.51M Buy
+32,545
New +$6.21M 2.76% 16
2022
Q2 		– Hold
0
– – – 71

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return